Yonsei Med J.  2007 Aug;48(4):678-683. 10.3349/ymj.2007.48.4.678.

Accuracy of a High Prostate-Specific Antigen Level for Prostate Cancer Diagnosis upon Initial Biopsy in Korean Men

• Shim HB
• Lee SE
• Park HK
• Ku JH

• KMID: 2158175
• DOI: http://doi.org/10.3349/ymj.2007.48.4.678

Abstract

PURPOSE
This study aimed to evaluate the cancer detection rate in a Korean population with prostate-specific antigen (PSA) levels greater than or equal to 20.0ng/mL. MATERIALS AND METHODS: A total of 174 men 50 to 79 years old (median 69) included in the study. The median prostate volume of the patients was 44.8mL (range 14.1 to 210.0) and their serum PSA ranged from 20.0 to 9725.0ng/mL (median 44.8). RESULTS: Of 174 men 141 (81.0%) were diagnosed with prostate cancer on initial biopsy. In the total number of patients, the positive predictive value (PPV) was 62.9% for PSA 20 to 29.9, 72.7% for PSA 30 to 39.9 and 100% for PSA 40 to 49.9 ng/mL. In patients with an abnormal digital rectal examination (DRE), the values for these PSA ranges increased to 89.5%, 91.7% and 100%, respectively. The PPV was 81.0% for PSA cutoff of 20, 89.2% for a cutoff of 30, 95.4% for a cutoff of 40, and 94.7% for a cutoff of 50 ng/mL. In conjunction with an abnormal DRE, the values for these PSA cutoffs increased to 95.9%, 98.1%, 100%, and 100%, respectively. CONCLUSION: Our data suggest the ability to predict the presence of prostate cancer reliably on initial biopsy when PSA threshold is greater than or equal to 50ng/mL. This PSA threshold may be lowered to 40ng/mL in the presence of an abnormal DRE. In Korean men with high PSA, the detection rate of prostate cancer on biopsy appears to be comparable to that for American men.

Keyword

Prostate-specific antigen; prostate neoplasms; prostate cancer; Asian

MeSH Terms

Aged
Biopsy
Cohort Studies
Digital Rectal Examination
Humans
Korea
Male
Middle Aged
Predictive Value of Tests
Prostate/pathology
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*diagnosis/metabolism/pathology

Reference

1. Carter HB. Prostate cancers in men with low PSA levels-must we find them? N Engl J Med. 2004. 350:292–294.

2. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin L, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994. 152:2031–2036.

3. Cooner WH, Mosley BR, Rutherford CL, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990. 143:1146–1152.

4. Heyns CF, Naudé AM, Ahmed G, Stopforth HB, Stellmacher GA, Visser AJ. Serum prostate-specific antigen as surrogate for the histological diagnosis of prostate cancer. S Afr Med J. 2001. 91:685–689.

5. Gerstenbluth RE, Seftel AD, Hampel N, Oefelein MG, Resnick MI. The accuracy of the increased prostate specific antigen level (greater than or equal to 20ng./ml.) in predicting prostate cancer: is biopsy always required? J Urol. 2002. 168:1990–1993.

6. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T, Girman CJ, et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: results of community based studies in 2 countries. J Urol. 1996. 155:1324–1327.

7. Ku JH. Race-specific reference ranges of serum prostate-specific antigen levels in countries with a low incidence of prostate cancer. BJU Int. 2006. 97:69–72.

8. Kim JW, Lee HY, Hong SJ, Chung BH. Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core?: a prospective randomized study in Korea. Yonsei Med J. 2004. 45:671–675.

9. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD, Kim SJ, et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study. Urology. 2006. 67:333–336.

10. Egawa S, Matsumoto K, Yoshida K, Iwamura M, Kuwao S, Koshiba K. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol. 1998. 28:666–672.

11. Song JM, Kim CB, Chung HC, Kane RL. Prostate-specific antigen, digital rectal examination and transrectal ultrasonography: a meta-analysis for this diagnostic triad of prostate cancer in symptomatic Korean men. Yonsei Med J. 2005. 46:414–424.

12. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992. 147:846–852.

13. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW. Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States. Urology. 1998. 51:186–195.

14. Yatani R, Shiraishi T, Nakakuki K, Kusano I, Takanari H, Hayashi T, et al. Trends in frequency of latent prostate carcinoma in Japan from 1965-1979 to 1982-1986. J Natl Cancer Inst. 1988. 80:683–687.

15. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993. 150:379–385.

16. Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, et al. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst. 1997. 89:1716–1720.

17. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000. 85:60–67.

18. Roberts RO, Bergstralh EJ, Besse JA, Lieber MM, Jacobsen SJ. Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980 to 1997. Urology. 2002. 59:79–84.